Plain-English translation of NCT07816692 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing the safety of iDose TR, a small implant that releases travoprost (a glaucoma medication) directly into the eye. The implant is placed during a quick procedure in a doctor's office rather than an operating room. Researchers want to make sure this treatment is safe and well-tolerated when given this way.
Currently, people with glaucoma often need to use eye drops every day, which can be inconvenient and hard to remember. This medication implant offers a potentially easier way to deliver treatment directly into the eye, and doctors want to confirm it works safely in an office setting.
You likely qualify if…
You likely don't qualify if…
You would visit a clinic to have the small implant placed directly into your eye during a brief office procedure. The study will then follow you to monitor how well you tolerate the treatment and check for any side effects. You'll likely have follow-up visits over time so the research team can ensure the implant is working safely for you.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States
Enrollment target
~30 participants
Started
May 2026
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Study Director
Glaukos Corporation
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.